Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650338 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Santen.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT00650338: Completed Phase 2 study, sponsored by Santen.
NCT00650338 is a Phase 2 study that has completed, run by Santen. The registered enrollment target is 165 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00650338, a Phase 2 study, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
Interventions
- DRUG Placebo
- DRUG 0.005% latanoprost
- DRUG DE-104 ophthalmic solution, low concentration
- DRUG DE-104 ophthalmic solution, medium concentration
- DRUG DE-104 ophthalmic solution, high concentration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00650338 record still lists
NCT00650338 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00650338 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00650338 about?
NCT00650338 is a clinical study titled "Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension". To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
What is the current status of trial NCT00650338?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2008-03. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00650338?
The interventions under investigation include: Placebo (DRUG), 0.005% latanoprost (DRUG), DE-104 ophthalmic solution, low concentration (DRUG), DE-104 ophthalmic solution, medium concentration (DRUG), DE-104 ophthalmic solution, high concentration (DRUG).
Who is sponsoring clinical trial NCT00650338?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00650338's enrollment target sits among peer trials
165 410th of 2000 higher than 1,588 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia